BE0974289218 - A2AJLU (XBRU)
ASIT BIOTECH S.A. Share
No Price
Current Prices from ASIT BIOTECH S.A.
Exchange | Ticker | Currency | Last Trade | Price | Daily Change | Daily Change % |
---|---|---|---|---|---|---|
London |
0RGO.L
|
EUR
|
21.10.2024 10:05
|
0,02 EUR
| 0,00 EUR | 0,00 % |
Performance
Day | Week | Month | 3 Months | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|---|
0,00 % | 0,00 % | 0,00 % | 6,90 % | -2,11 % | 16,25 % | -91,55 % |
Company Profile for ASIT BIOTECH S.A. Share
DMS Imaging SA, a biopharmaceutical company, focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies in Belgium. Its lead product is gp-ASIT+, which is in the Phase III trial for the treatment of grass pollen. The company is also developing hdm-ASIT+ for the treatment of house dust mite allergy; and pnt-ASIT+ for the treatment of peanut allergy. The company was formerly known as ASIT Biotech S.A. and changed its name to DMS Imaging SA in February 2022. DMS Imaging SA was incorporated in 1997 and is based in Liege, Belgium.
Company Data for ASIT BIOTECH S.A. Share
Name ASIT BIOTECH S.A.
Company DMS Imaging SA
Website https://www.dms.com
Primary Exchange
EURONEXT - EURONEXT BRUSSELS
WKN A2AJLU
ISIN BE0974289218
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Mr. Frank Hazevoets
Market Capitalization 31 Mio
Country Belgium
Currency EUR
Employees 0,1 T
Address 7 Rue des Chasseurs Ardennais, 4031 Liège
IPO Date 2023-01-24
Ticker Symbols
Name | Symbol |
---|---|
Frankfurt | AS0.F |
London | 0RGO.L |
More Shares
Investors who ASIT BIOTECH S.A. hold also have the following shares in their portfolio:
The financial platform MoneyPeak tracks and analyzes investments and portfolios.
From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.